Trial Profile

A 2-part Phase 1/2 Open-label Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ODM-212 in Combination With Anti-cancer Therapy in Participants With Advanced Solid Tumours

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ODM-212 (Primary) ; Gemcitabine; Ipilimumab; Nivolumab; Paclitaxel; Sotorasib
Indications Adenocarcinoma; Mesothelioma; Non-small cell lung cancer; Pancreatic cancer
Focus Adverse reactions; Therapeutic Use
Acronyms TEADCO
Sponsors Orion Pharma

06 May 2026 New trial record
23 Apr 2026 According to Orion Pharma media release, announced the initiation of a Phase 1b/2 basket trial evaluating ODM-212, a potential best-in-class, oral pan-TEAD inhibitor, in combination with standard of care treatments in Solid tumors..

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com